NFL Biosciences (STU:82F) Debt-to-Equity : 0.18 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Debt-to-Equity?

NFL Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.06 Mil. NFL Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. NFL Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €0.35 Mil. NFL Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NFL Biosciences's Debt-to-Equity or its related term are showing as below:

STU:82F' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.18 Max: 0.65
Current: 0.18

During the past 6 years, the highest Debt-to-Equity Ratio of NFL Biosciences was 0.65. The lowest was 0.03. And the median was 0.18.

STU:82F's Debt-to-Equity is ranked worse than
53.09% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs STU:82F: 0.18

NFL Biosciences Debt-to-Equity Historical Data

The historical data trend for NFL Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Debt-to-Equity Chart

NFL Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.57

0.03

0.10

0.18

NFL Biosciences Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			0.03	0.04	0.10	0.08	0.18

Competitive Comparison of NFL Biosciences's Debt-to-Equity

For the Biotechnology subindustry, NFL Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's Debt-to-Equity falls into.

NFL Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NFL Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.062	+	0)	/	0.35
	=	0.18

NFL Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.062	+	0)	/	0.35
	=	0.18

NFL Biosciences (STU:82F) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NFL Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (STU:82F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (STU:82F) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ALNFL:France 82F:Germany

Address

199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170

Website

https://www.nflbiosciences.com/

NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (STU:82F) Headlines

No Headlines